Market Capitalization

The blank-check firm's successful debut signals renewed, selective investor appetite for SPACs with a sharp focus on high-growth Israeli technology.

Fresh off strong financial growth, Web3 fintech firm Antalpha is pivoting into AI, launching proprietary routing tech to bridge AI and digital assets.

LMC Landscape Partners' latest acquisition of Prestige Landscape Services signals a new era of consolidation in the booming Dallas-Fort Worth market.

A secretive Department of War initiative partners a quantum tech firm with special ops experts to deploy a revolutionary battlefield detection system.

With a new chairman known for strategic acquisitions, LeoLabs is signaling an aggressive push into missile defense and a new era as a defense 'neoprime'.

Mohammad Khadar was just named IHOP's Franchisee of the Year. Here's how he built a multi-state dining empire on a foundation of hospitality and strategy.

Atlanta is the new #1 sports business city. Discover the playbook, metrics, and national trends driving this urban gold rush for economic dominance.

AI hardware innovator Cerebras Systems closes a massive $6.38B IPO, signaling a new front in the battle against NVIDIA with its unique wafer-scale chip.

Fresh off its IPO, Agomab Therapeutics is presenting key data for its new IPF drug, AGMB-447, while courting investors on a multi-conference tour.

Malaysian aquaculture firm Megan Holdings' stock has plummeted, triggering a Nasdaq delisting warning and a six-month race to regain compliance.

As the space economy booms, a top TMT research firm launches dedicated coverage, signaling a new era of financial scrutiny for giants like SpaceX and Rocket Lab.

The Fortune 250 retailer's 10% dividend hike reflects strong financials and a strategic navigation of a complex, evolving automotive landscape.

The cell-engineering firm posted a smaller-than-expected loss and announced a share buyback, signaling confidence despite a dip in core Q1 revenue.

As Fabrinet preps for a key J.P. Morgan conference, record revenues clash with supply chain woes, putting its role in the AI revolution under a microscope.

Cadre Holdings reports a record $355M backlog and higher sales, yet profits fall sharply due to acquisition costs, signaling a high-stakes growth strategy.

The specialty manufacturer reports a 46% profit surge, fueled by strong demand for its key drug and a major distributor's comeback. What's next?

The former solar EV pioneer has completed its radical pivot, selling its solar business to management and betting its entire future on Bitcoin.

The biotech supplier swung to profitability and positive cash flow, driven by a major cost overhaul and strong demand in its core nucleic acid business.

As Talphera preps its Q1 update, all eyes are on its breakthrough drug Niyad® and the mounting costs of bringing a potential game-changer to market.

With key clinical data on the horizon for its cancer and ALS drugs, LeonaBio adds deep financial, operational, and strategic expertise to its leadership.